SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
This is a press release announcing the timing and logistics of SNDL's second quarter 2026 financial results release scheduled for July 28, 2026. While the actual results are not yet disclosed in this exhibit, the announcement of an upcoming earnings release is a material event that informs investors of when quarterly financial results will be available. The disclosure includes the release date, time, and webcast access details for the earnings call.
View raw filing on EDGAR →This is a press release announcing TRX Gold's third quarter 2026 financial results for the three and nine months ended May 31, 2026. The document discloses quarterly revenue of $32.9 million, gross profit of $19.5 million, adjusted EBITDA of $20.7 million, and gold production of 7,426 ounces poured and 6,983 ounces sold, along with year-to-date results and operational metrics. The CEO commentary and detailed financial tables are characteristic of a quarterly earnings release, which is a material event affecting investor assessment of the registrant's financial performance and operational progress.
View raw filing on EDGAR →Centerra Gold announces an amendment to its revolving credit facility that extends the maturity to July 15, 2030, and increases the facility size from US$400 million to US$600 million on improved terms (lower interest margins). This constitutes a material amendment to an existing direct financial obligation. While the facility is undrawn as of the announcement date, the expansion and refinement of credit terms represents a significant capital structure event that would affect a reasonable investor's assessment of the company's financial flexibility and cost of capital.
View raw filing on EDGAR →Ceragon announced a $3.4 million two-year managed services contract with a major mobile operator in Mexico, covering SLA-based support for approximately 2,290 network links. This is a material operational and commercial event—a significant new customer engagement that demonstrates market traction and reinforces the company's strategic position in Latin America, particularly when combined with the previously announced $2.7 million Colombia contract. While not a discrete M&A transaction, it is a material business development that would affect a reasonable investor's assessment of revenue prospects and customer relationships.
View raw filing on EDGAR →The filing discloses receipt of over $20 million in orders from a leading global satellite operator for SkyEdge services and systems, with most deliveries expected within 24 months. This represents a material customer contract award that would affect a reasonable investor's assessment of the registrant's revenue pipeline and market position. While not a discrete M&A transaction, debt issuance, or other specifically-named event type, it is a material operational/commercial milestone reflecting customer demand and business momentum.
View raw filing on EDGAR →This press release announces the expansion of PRF's DeepSolar Predict™ platform with a new "Battery-to-Revenue Intelligence" capability and plans for a "What-if Battery Scenario" feature, alongside validation of the platform using real-world European market data and advancement toward planned commercial launch. The disclosure is a product development and strategic milestone announcement—an operational/business event—rather than a discrete financial, governance, or legal event. It is material because it describes significant progress on a core product platform (DeepSolar/GridFeed) that the company positions as central to its energy optimization business strategy and future revenue generation.
View raw filing on EDGAR →Frequency Electronics issued a press release on July 15, 2026 announcing financial results for the fiscal year ended April 30, 2026, disclosing revenue of $63.2 million, operating loss of $3.0 million, and net loss of $0.9 million per diluted share. The filing also includes forward-looking guidance establishing a three-year minimum revenue target of $150 million and margin targets (50% gross margin, 30% operating margin by Fiscal 2029), along with discussion of a $111 million funded backlog. This is a standard earnings release disclosure under Item 2.02.
View raw filing on EDGAR →Fractyl Health disclosed positive one-year clinical trial results from its REMAIN-1 Midpoint Cohort for the Revita DMR System, demonstrating that 81–84% of GLP-1-induced weight loss was retained versus 46–48% with sham, with excellent tolerability and no serious adverse events. The company anticipates FDA De Novo submission in late Q4 2026, representing a material clinical milestone for its lead product candidate.
View raw filing on EDGAR →UMC's subsidiary Fortune Venture Capital Corporation disposed of 3,706,000 shares of Taiwan Semiconductor Co., Ltd. between January and July 2026, realizing a gain of NTD 137.6 million. The transaction is disclosed as a material asset disposal for financing purposes. While the shareholding ratio (1.15%) and transaction size relative to total assets (2.42%) are modest, the gain is material and the disclosure is required under Taiwan securities regulations for asset disposals by public companies. This is a financial event—specifically a divestiture—that does not fit the narrower categories of M&A activity or debt issuance.
View raw filing on EDGAR →SK hynix issued 17.79 million new common shares via third-party allotment to Citibank (the depositary) for approximately US$26.5 billion, with the shares serving as the basis for ADRs issued to overseas institutional investors. This is a material unregistered equity issuance that dilutes existing shareholders and raises substantial capital, fitting the definition of dilutive_issuance.
View raw filing on EDGAR →SemiLEDs received a Nasdaq delisting notice on January 30, 2026 for failing to meet the minimum $2.5 million stockholders' equity requirement under Listing Rule 5550(b)(1). Although the company claims to have regained compliance as of May 31, 2026 with $3.1 million in equity, Nasdaq retains the right to delist if compliance is not evidenced at the next periodic report. This is a classic delisting-risk disclosure under Item 3.01, material to investors assessing the registrant's continued exchange listing status.
View raw filing on EDGAR →BlackRock disclosed its second quarter and first-half 2026 financial results on July 15, 2026, reporting diluted EPS of $12.19 (or $13.91 as adjusted), $15.3 trillion in AUM, record net inflows of $321 billion year-to-date, revenue of $7.084 billion, operating income of $2.461 billion, and 31% revenue growth year-over-year.
View raw filing on EDGAR →Pediatrix issued a press release on July 15, 2026 providing a second quarter 2026 business update, reaffirming full-year 2026 Adjusted EBITDA guidance of $280–$300 million and confirming stable payor mix and revenue trends. The company also announced a detailed earnings conference call for August 4, 2026.
View raw filing on EDGAR →The disclosure announces FDA acceptance of a New Drug Application (NDA) filing for AXS-12 (reboxetine) for cataplexy in narcolepsy, with a PDUFA target action date of May 1, 2027. This is a material regulatory milestone in the drug development process—a critical step toward potential commercialization of a product candidate. While not a final approval, NDA acceptance is a significant operational and strategic event that would affect investor assessment of the company's pipeline progress and commercial prospects. This does not fit the specific categories of earnings release, M&A, impairment, or other named types, making it an operational milestone best classified as operational_other.
View raw filing on EDGAR →Worthington Steel announced the opening of the acceptance period for a public delisting tender offer for all outstanding shares of Klöckner & Co SE not already held by Worthington Steel. This constitutes a material acquisition activity—specifically the continuation of a change-of-control transaction. Worthington Steel already holds approximately 62% of Klöckner following completion of its Voluntary Public Takeover Offer on June 3, 2026, and this delisting offer represents the squeeze-out phase to acquire remaining shares at EUR 11.00 per share. This is a material M&A event requiring 8-K disclosure under Item 1.01 or 2.01 framework.
View raw filing on EDGAR →Genasys entered into a Third Amendment to its Term Loan and Security Agreement, extending the maturity date from July 13, 2026 to July 13, 2027 and restructuring repayment terms from quarterly interest plus a balloon payment to monthly amortization payments of $1.0 million beginning October 1, 2026. The amendment also introduces a guaranteed minimum return (MOIC) of 20% and materially modifies the Company's direct financial obligations and liquidity profile.
View raw filing on EDGAR →Nuvalent completed a merger on July 15, 2026, whereby it became a wholly owned subsidiary of Parent following acceptance of all tendered shares in a tender offer and consummation pursuant to Section 251(h) of the DGCL, representing a change of control transaction with an equity value of approximately $10.6 billion.
View raw filing on EDGAR →Following the merger completion, Nuvalent notified Nasdaq of the transaction and requested a halt and suspension of trading in its shares, with delisting from Nasdaq and deregistration under Section 12(b) of the Exchange Act to follow, along with intended filing of Form 15 to suspend reporting obligations.
View raw filing on EDGAR →This announcement discloses the grant of 1,255,122 restricted share units (RSUs) to 47 employees on July 15, 2026, pursuant to the 2025 Share Incentive Scheme. The disclosure details the vesting schedules, terms, and conditions of the equity awards. Although the grantees are employees rather than named executives, this is a material compensatory arrangement involving equity grants that would affect investor assessment of the company's capital structure and employee incentive practices. The RSUs represent approximately 0.07% of issued shares and are subject to service-based vesting conditions over multiple years.
View raw filing on EDGAR →Cameco announced resumption of production at its Cigar Lake mine following a temporary suspension caused by challenges at Orano's McClean Lake mill. The company confirms its 2026 production outlook of 17.5–18.0 million pounds of U3O8 remains unimpacted. This is an operational milestone—the restart of a major production facility—that would affect investor assessment of the company's ability to meet guidance and generate revenue, but it does not fit the specific event categories of M&A, workforce reduction, material impairment, or other named types. The disclosure is material because production resumption at a flagship asset directly impacts financial performance and investor confidence.
View raw filing on EDGAR →AFS SenSub Corp. and GM Financial caused the issuance of approximately $1.016 billion in asset-backed notes across multiple classes (Class A-1 through Class C) on July 15, 2026. This constitutes creation of a new direct financial obligation through debt issuance, which is a material capital event requiring 8-K disclosure under Item 2.03 (though filed under Item 8.01). The magnitude and structured nature of the securitization make this material to investors.
View raw filing on EDGAR →Ian Ratcliffe, an independent director on the Board since February 2024, passed away on July 5, 2026. While the filing also mentions a board size reduction and appointment of Nicholas Naclerio to the Audit Committee, the principal disclosed event is the departure of a director due to death. This is material as it affects board composition and governance structure.
View raw filing on EDGAR →The filing discloses the appointment of Reza Zadno, Ph.D. as a new director to Mobia Medical's Board, increasing the Board size from six to seven members. Dr. Zadno was also appointed to the Compensation Committee as an independent director. This is a clear executive appointment event under Item 5.02(d), and is material as board composition changes affect corporate governance and investor assessment of the company's leadership structure.
View raw filing on EDGAR →The Company declared a special cash dividend of $1.05 per share and an annual cash dividend of $0.95 per share, totaling approximately $23.6 million in aggregate payments to stockholders. This is a clear dividend distribution event under the taxonomy, material to investors as it represents a significant capital return and reflects the Company's financial performance and capital allocation strategy.
View raw filing on EDGAR →This disclosure reports the Company's monthly Net Asset Value (NAV) per share as of June 30, 2026, calculated in accordance with board-approved valuation guidelines. The filing provides detailed breakdowns of NAV components (commercial mortgage loans, real estate owned, liabilities, etc.) and NAV per share for each share class ($13.2318 aggregate). For a non-traded REIT, NAV per share is a critical metric for investor valuation and redemption pricing, making this a material financial disclosure that would affect a reasonable investor's assessment of the registrant's value, though it does not fit the specific categories of earnings release, impairment, debt issuance, or other named financial events.
View raw filing on EDGAR →The disclosure centers on compensatory arrangements for a departing officer: a severance agreement providing $365,775.12 in severance, COBRA premium coverage, conditional change-in-control benefits (18 months base salary plus 2026 bonus target), and a consulting agreement at $1,000/hour. While Valerie Barnett's departure as Chief Legal Officer occurred on June 29, 2026, the material 8-K event filed on July 15 focuses on the severance and consulting compensation arrangements negotiated on July 9, 2026, making this primarily an exec_compensation disclosure under Item 5.02(e).
View raw filing on EDGAR →On July 15, 2026, Celsius Holdings entered into a second refinancing amendment to its Credit Agreement, reducing the applicable interest rate on the Term Loan Facility by 0.25% with potential for an additional 0.25% reduction. The Company issued a new $694.75 million term loan to repay the existing $700.0 million term loan, materially affecting its debt structure and interest expense.
View raw filing on EDGAR →Aziz Mottiwala was appointed as President and Chief Executive Officer effective July 20, 2026, replacing Ron Kurtz, M.D., who transitioned to Chief Medical Officer. Mottiwala was also appointed to the Board of Directors with detailed employment terms including $14 million in equity awards.
View raw filing on EDGAR →The filing announces that Diodes will distribute its second quarter 2026 financial results on August 5, 2026, and host a conference call to discuss those results. Although the actual earnings announcement is scheduled for a future date, the press release itself constitutes an advance notice of the earnings release event. The disclosure of quarterly financial results is material to investors and affects the total mix of information available about the registrant's financial performance.
View raw filing on EDGAR →The disclosure announces a Board-authorized share repurchase program for up to $55 million total ($20 million Series B and $35 million Series C preferred stock). While repurchase programs are capital allocation decisions, they function as a return of capital to shareholders similar to dividends. The materiality threshold ($55 million authorization) and the explicit framing as a "capital allocation strategy" affecting shareholder value support classification as a material capital distribution event. This is best captured under dividend_distribution, which encompasses share-repurchase programs and returns of capital to holders.
View raw filing on EDGAR →Aldeyra disclosed receipt of FDA meeting minutes regarding potential resubmission of a New Drug Application (NDA) for reproxalap and plans to request a Type D meeting with the FDA by Q3 2026. This is a material regulatory milestone in the drug development process that would affect investor assessment of the company's pipeline progress, but does not fit the specific categories of earnings, M&A, impairment, litigation, or other named event types. The disclosure centers on an operational/regulatory development rather than a financial or governance event.
View raw filing on EDGAR →Runway Growth Finance Corp. entered into an eighth amendment to its credit agreement that materially modifies the existing credit facility, reducing the commitment from $550 million to $425 million and modifying financial covenants and borrowing base criteria.
View raw filing on EDGAR →This disclosure reports the Fund's net asset value (NAV) per share as of May 31, 2026, along with aggregate NAV, portfolio fair value, and debt-to-equity ratio. While NAV reporting is a routine financial disclosure for closed-end funds, the specific NAV figure and leverage metrics are material to investors assessing the Fund's financial position and performance. This does not fit a more specific financial event category (earnings release, impairment, debt issuance, etc.) and is best classified as a financial reporting event.
View raw filing on EDGAR →The 6-K discloses a grant of 14,060 warrants to employees on July 14, 2026, with an exercise price of $265.57 per share and a four-year vesting schedule (25% at one year, then 1/36th monthly). This is a compensatory arrangement for named executives and employees under the company's Articles of Association, materially affecting equity incentive arrangements and shareholder dilution.
View raw filing on EDGAR →Obsidian Energy announces entry into an underwriting agreement to sell an additional $75 million aggregate principal amount of 8.125% senior unsecured notes due December 3, 2030, increasing total outstanding notes from $175 million to $250 million. This is a material creation of new direct financial obligation under Item 2.03 of the 8-K taxonomy, with gross proceeds of $77.1 million to be used for debt paydown and general corporate purposes.
View raw filing on EDGAR →John C. Roche, the current President and CEO and Board member, is retiring effective December 31, 2026. While the filing also announces Richard W. Lavey's appointment as CEO-Elect, the primary disclosed action centers on Roche's departure after a 40-year insurance career and 20 years with the company. The retirement of a sitting CEO is material to investors assessing leadership continuity and company direction.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from the 2026 Annual Meeting of Stockholders held on July 14, 2026. The filing reports final voting tallies for three proposals: election of three Class II directors (Patricia Gauthier, Jonathan Lieber, and Frederick E. Pierce), non-binding advisory approval of named executive officer compensation, and ratification of Ernst & Young LLP as independent auditor. This is the quintessential shareholder_vote_results event type under Item 5.07.
View raw filing on EDGAR →Q32 Bio entered into an underwriting agreement to issue 6,027,399 shares of common stock at $18.25 per share and 4,931,506 pre-funded warrants, raising approximately $187.6 million (or $215.8 million with optional shares exercised). This is a material registered public offering of equity securities that will dilute existing shareholders and is a significant capital-raising event for the company's clinical development efforts.
View raw filing on EDGAR →SBA Communications entered into an underwriting agreement on July 14, 2026 to issue $3.5 billion in aggregate principal amount of senior notes across three tranches (4.875% due 2030, 5.150% due 2031, and 5.450% due 2033) in a registered public offering. The company intends to use net proceeds to repay existing senior secured term loan and revolving credit facility obligations. This is a material creation of new direct financial obligations through debt issuance.
View raw filing on EDGAR →Catalyst Pharmaceuticals completed a merger transaction in which the Company became a wholly owned subsidiary of Parent, resulting in a change of control. All seven directors resigned and were replaced by three directors of Merger Sub, and Company Common Stock was converted into merger consideration. The Company notified Nasdaq of its intent to delist effective July 16, 2026, and intends to file Form 15 to terminate SEC registration and reporting obligations.
View raw filing on EDGAR →Polibeli Group entered into a non-binding Memorandum of Understanding on July 1, 2026, with PT Grosirone Prima Nusantara to evaluate a potential AI data center project in Indonesia with planned power capacity of up to 10MW. While the MOU is explicitly non-binding and subject to future due diligence, financing, and regulatory approvals, the disclosure of a strategic expansion into AI data center infrastructure represents a material operational and business development initiative that would affect a reasonable investor's assessment of the company's growth strategy and market opportunities.
View raw filing on EDGAR →The press release announces an extension of the deadline for shareholders to submit payment instructions for a previously declared special cash dividend of US$55.00 per common share. Although this is an administrative extension rather than a new dividend declaration, it relates directly to the distribution of a material capital return to shareholders and would affect investor assessment of dividend receipt timing and procedures.
View raw filing on EDGAR →The 6-K discloses results of an annual general meeting of shareholders held on July 13, 2026, where shareholders voted on three proposals: (1) a share consolidation proposal (approved 256,359,455 for), (2) an M&A notice amendment proposal (approved 256,418,884 for), and (3) an adjournment proposal (approved 256,592,808 for). This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent, with detailed voting tallies and outcomes. The share consolidation authorization (up to 1-for-400) and bylaw amendments are material governance matters affecting capital structure and shareholder rights.
View raw filing on EDGAR →This press release announces POMDOCTOR's strategic advancement of its healthcare data asset strategy and AI-powered chronic disease management capabilities. The disclosure describes the company's development of a comprehensive healthcare data ecosystem leveraging real-world data, wearables, remote patient monitoring, and AI analytics. While this is a strategic operational announcement about the company's technology and business direction rather than a discrete event (M&A, executive change, financial result, or litigation), it is material to investors as it articulates the company's core competitive positioning and long-term value creation strategy in the AI healthcare space.
View raw filing on EDGAR →The Company announces termination of its ADR program and mandatory cancellation of ADSs, with Class A ordinary shares to trade directly on Nasdaq under a new symbol "QH" effective July 17, 2026. While this is a shareholder-approved listing transition rather than a delisting per se, it represents a material change in the trading venue and security structure (share consolidation at 32,000:1 ratio) that affects how existing ADS holders will hold and trade the underlying shares. The mandatory conversion and consolidation constitute a material restructuring of the equity security and its trading mechanism.
View raw filing on EDGAR →This press release announces a clinical trial milestone: successful treatment of the first patient in the ADMIRE study, a company-sponsored clinical trial evaluating Alpha DaRT for immunocompromised patients with recurrent cutaneous squamous cell carcinoma. The disclosure highlights the expansion of Alpha Tau's clinical program into a new patient population (immunocompromised patients) and represents progress toward potential regulatory approval and commercialization of its core therapeutic technology. While not a discrete M&A, financing, or governance event, this clinical milestone is material to investors assessing the company's pipeline development and commercial prospects, particularly given Alpha Tau's dependence on Alpha DaRT success and the company's limited operating history.
View raw filing on EDGAR →The press release announces the appointment of John M. Melkon to the board of directors of Skyline Builders Group Holding Limited, effective immediately. The disclosure also notes that Ngo Chiu Lam is stepping down from the board concurrently. The appointment of a director with significant expertise in critical materials supply chains and geopolitical operations is material to investors evaluating the company's strategic pivot from Asian construction to critical minerals supply, particularly given the pending merger with Cove Kaz and the company's stated objective to become a strategic supplier to the U.S. defense and industrial base.
View raw filing on EDGAR →Cadiz received a Right-of-Way Grant from the BLM authorizing conversion of its Northern Pipeline to water conveyance on federal lands, completing a major regulatory milestone. The Grant enables the Company to proceed with construction of a 220-mile pipeline with capacity to deliver 25,000 acre-feet of water annually, with 85% already contracted to water providers. This is a material operational and strategic event—the removal of a key regulatory barrier to a significant infrastructure project—but does not fit the specific categories of M&A, debt, equity, or other named event types.
View raw filing on EDGAR →Regentis announced European Notified Body approval of a next-generation, solvent-free manufacturing process for GelrinC® that increases production yield by 400% and improves scalability ahead of European commercial launch. This is a material operational and regulatory milestone—the approval enables commercial manufacturing with substantially improved efficiency and cost structure—but does not fit the discrete event categories (not an earnings release, M&A, impairment, litigation, or executive change). The disclosure is clearly operational/strategic in nature and would affect a reasonable investor's assessment of the company's ability to commercialize its lead product profitably.
View raw filing on EDGAR →The filing discloses termination of a non-binding letter of intent for a proposed business combination between SC II Acquisition Corp. (a SPAC controlled by T3 Defense's subsidiary) and a payments technology company. Although the LOI was non-binding, the termination of a material acquisition transaction that was previously disclosed and contemplated by the registrant's affiliate constitutes a material M&A event. The disclosure explicitly states the SPAC "is terminating the LOI, effective immediately, as the SPAC does not intend to pursue the Proposed Transaction," which is a clear termination of M&A activity.
View raw filing on EDGAR →